NDC product
Lisdexamfetamine Dimesylate
NDC 0406-5127 · SpecGx LLC
Key facts
| Product NDC | 0406-5127 |
|---|---|
| Proprietary name | Lisdexamfetamine Dimesylate |
| Nonproprietary name | Lisdexamfetamine Dimesylate |
| Substances | LISDEXAMFETAMINE DIMESYLATE |
| Dosage form | TABLET, CHEWABLE |
| Route | ORAL |
| Labeler | SpecGx LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA218850 |
| DEA schedule | CII |
| Pharmacologic classes | Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE] |
| Marketing start | Dec 17, 2024 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: